Descovy
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead’s nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and Vemlidy (tenofovir alafenamide [TAF]). The combination is currently approved in the US, Japan, and EU.
Descovy has achieved rapid initial uptake in both the US and EU, driven by its superior renal and bone safety profile compared to its predecessor, Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco). With an aging HIV-infected population and increasing scrutiny of the long-term safety of HIV treatments, Descovy’s potential to reduce the real-world incidence of renal dysfunction and bone fractures has allowed it to quickly cannibalize Truvada’s remaining market share within the US and select EU markets. However, within more cost-conservative EU markets, such as the UK, the launch of generic versions of Truvada is a substantial threat to Descovy’s continued growth, as some payers may mandate use of the generic emtricitabine + TDF backbone for patients who are not perceived as being at higher risk of bone or renal disease.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Descovy : HIV
LIST OF FIGURES
11 Figure 59: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
14 Figure 61: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
LIST OF TABLES
6 Table 1: Descovy drug profile
6 Table 2: Approval history of Descovy for HIV in the US, Japan, and five major EU markets
8 Table 3: Late-phase trials of Descovy for HIV
10 Table 4: Descovy for HIV – SWOT analysis
12 Table 87: Late-phase trials of fostemsavir for HIV
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the